Please wait a minute...
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (2): 227-231    DOI: 10.3785/j.issn.1008-9292.2020.03.06
    
Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab
LUO Song1(),YANG Lijuan2,WANG Chun1,LIU Chuanmiao3,LI Dianming4
1. Department of Neurology, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China
2. Department of Pediatrics, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China
3. Department of Infectious Diseases, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China
4. Department of Respiratory Medicine, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China
Download: HTML( 32 )   PDF(1042KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To observe the clinical effect of plasma exchange and tocilizumab in treatment of patients with severe coronavirus disease 2019 (COVID-19). Methods: Six patients with severe COVID-19 admitted in First Affiliated Hospital of Bengbu Medical College from January 25 to February 25, 2020. Three patients were treated with plasma exchange and three patients were treated with tocilizumab. The effect on excessive inflammatory reaction of plasma exchange and tocilizumab was observed. Results: The C-reactive protein (CRP) and IL-6 levels were significantly decreased and the lymphocyte and prothrombin time were improved in 3 patients after treatment with plasma exchange; while inflammation level was not significantly decreased, and lymphocyte and prothrombin time did not improve in 3 patients treated with tocilizumab. Conclusion: For severe COVID-19 patients with strong inflammatory reaction, plasma exchange may be preferred.



Key wordsCoronavirus disease 2019      Severe acute respiratory syndrome coronavirus 2      Novel coronavirus pneumonia      Critical illness      Plasma exchange      Tocilizumab     
Received: 06 March 2020      Published: 13 March 2020
CLC:  R512.99  
Cite this article:

LUO Song,YANG Lijuan,WANG Chun,LIU Chuanmiao,LI Dianming. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab. J Zhejiang Univ (Med Sci), 2020, 49(2): 227-231.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.03.06     OR     http://www.zjujournals.com/med/Y2020/V49/I2/227


血浆置换和托珠单抗治疗六例2019冠状病毒病(COVID-19)重型患者临床分析

目的: 分析血浆置换和托珠单抗治疗2019冠状病毒病(COVID-19)重型患者的疗效。方法: 回顾性分析2020年1月25日至2月25日在蚌埠医学院第一附属医院感染应急病区接受治疗的6例COVID-19重型患者的临床资料(3例采用血浆置换治疗,3例采用托珠单抗治疗)。观察血浆置换和托珠单抗治疗对患者体内过度炎症反应的抑制作用。结果: 血浆置换治疗后,3例患者C反应蛋白和IL-6水平下降明显,淋巴细胞和凝血酶原时间均有改善;托珠单抗治疗后,3例患者炎症水平未见明显下降,淋巴细胞计数和凝血酶原时间也无明显改善。结论: COVID-19重型患者采用血浆置换治疗后炎症因子水平明显降低或恢复正常,而托珠单抗治疗患者炎症因子下降不明显。因此对于炎症反应强烈的COVID-19重型患者,血浆置换可能是首选。


关键词: 2019冠状病毒病,  严重急性呼吸综合征冠状病毒2,  新型冠状病毒肺炎,  危重病,  血浆置换,  托珠单抗 
例序 白细胞计数
(×109/L)
淋巴细胞计数
(×109/L)
血小板计数
(×109/L)
血红蛋白
(g/L)
ALT
(U/L)
AST
(U/L)
总胆红素
(μmol/L)
肌酐
(μmol/L)
PT(s) C反应蛋白
(mg/L)
IL-6
(pg/mL)
  ALT:丙氨酸转氨酶;AST:天冬氨酸转氨酶;PT:凝血酶原时间.
病例1
  治疗前 4.36 0.56 158 142 33 47 14.8 70 12.4 84.81 12.14
  治疗后 9.31 1.26 260 139 12 18 5.8 62 11.3 9.20 4.33
病例2
  治疗前 10.59 1.07 205 134 30 41 10.6 66 12.8 123.1 12.20
  治疗后 11.22 2.72 209 139 26 37 10.5 66 11.7 20.1 2.55
病例3
  治疗前 8.84 0.52 203 136 17 34 29.1 59 13.9 196.3 142.90
  治疗后 8.05 0.79 142 116 49 40 16.0 58 12.5 84.2 6.48
Tab 1 Results of laboratory examination of COVID-19 patients before and after plasma exchange
例序 白细胞计数
(×109/L)
淋巴细胞计数
(×109/L)
血小板计数
(×109/L)
血红蛋白
(g/L)
ALT
(U/L)
AST
(U/L)
总胆红素
(μmol/L)
肌酐
(μmol/L)
PT(s) C反应蛋白
(mg/L)
IL-6
(pg/mL)
  ALT:丙氨酸转氨酶;AST:天冬氨酸转氨酶;PT:凝血酶原时间.
病例4
  治疗前 5.25 0.84 181 113 30 50 16.8 59 10.3 35.35 75.52
  治疗后 8.74 1.80 294 122 51 26 8.6 67 10.9 7.63 62.43
病例5
  治疗前 8.36 1.99 246 127 17 33 11.7 77 14.0 74.3 15.67
  治疗后 6.67 1.74 265 120 22 26 8.5 87 15.0 15.9 16.34
病例6
  治疗前 14.23 0.62 235 124 16 20 4 60 10.3 24.6 13.39
  治疗后 6.35 0.61 232 118 15 17 7.1 61 11.1 8.8 17.98
Tab 2 Results of laboratory examination of COVID-19 patients before and after tocilizumab treatment
[1]   YANG P H , ING Y B , X UZ et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China[J]. medRrxiv, 2020,
doi: 10.1101/2020.02.28.20028068
[2]   HUANG C , WANG Y , LI X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395 (10223): 497- 506
doi: 10.1016/S0140-6736(20)30183-5
[3]   CHEN N , ZHOU M , DONG X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395 (10223): 507- 513
doi: 10.1016/S0140-6736(20)30211-7
[4]   中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第七版)[A/OL].国卫办医函〔2020〕184号. (2020-03-03)[2020-03-04].http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html.
General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of novel coronavirus pneumonia (trial version 7)[A/OL]. No.184〔2020〕 of the General Office of the National Health Commission. (2020-03-03)[2020-03-04].http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html. (in Chinese)
[5]   LAI H S, LIN W H, LAI S L, et al. Interleukin-6 mediates angiotensinogen gene expression during liver regeneration[J/OL]. PLoS One, 2013, 8(7): e67868. DOI: 10.1371/journal.pone.0067868.
[6]   TISONCIK J R , KORTHM J , SIMMONS C P et al. Into the eye of the cytokine storm[J]. Microbiol Mol Biol Rev, 2012, 76 (1): 16- 32
doi: 10.1128/MMBR.05015-11
[7]   D'ELIA R V , HARRISON K , OYSTON P C et al. Targeting the "cytokine storm" for therapeutic benefit[J]. Clin Vaccine Immunol, 2013, 20 (3): 319- 327
doi: 10.1128/CVI.00636-12
[8]   HE L , DING Y , ZHANG Q et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS[J]. J Pathol, 2006, 210 (3): 288- 297
doi: 10.1002/path.2067
[9]   RUFINO HERNáNDEZ M , ESCAMILLA CABRERA B , ALVAREZ SOSA D et al. Patients treated with plasmapheresis: a case review from University Hospital of the Canary Islands[J]. Nefrologia, 2011, 31 (4): 415- 434
doi: 10.3265/Nefrologia.pre2011.Apr.10640
[10]   HARM S , FALKENHAGEN D , HARTMANN J . Endotoxin adsorbents in extracorporeal blood purification: do they fulfill expectations?[J]. Int J Artif Organs, 2014, 37 (3): 222- 232
doi: 10.5301/ijao.5000304
[11]   RUFINO HERNáNDEZ J M , CABELLO MOYA E , GONZáLEZ-POSADA J M et al. Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft[J]. Nefrologia, 2010, 30 (2): 252- 257
doi: 10.3265/Nefrologia.pre2010.Jan.10233
[12]   LU L , LUO G , XIAO F . A retrospective survey of the quality of reports and their correlates among randomized controlled trials of immunotherapy for Guillain-Barré syndrome[J]. Immunotherapy, 2013, 5 (8): 829- 836
doi: 10.2217/imt.13.75
[13]   LEHMANN H C , HARTUNG H P . Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies[J]. J Neuroimmunol, 2011, 231 (1-2): 61- 69
doi: 10.1016/j.jneuroim.2010.09.015
[14]   NAM J L , TAKASE-MINEGISHI K , RAMIRO S et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis[J]. Ann Rheum Dis J, 2017, 76 (6): 1113- 1136
doi: 10.1136/annrheumdis-2016-210713
[1] WANG Jincheng,LIU Jinpeng,WANG Yuanyuan,LIU Wei,CHEN Xiaoqun,SUN Chao,SHEN Xiaoyong,WANG Qidong,WU Yaping,LIANG Wenjie,RUAN Lingxiang. Dynamic changes of chest CT imaging in patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 191-197.
[2] ZHANG Xiaoyan, SUN Wei, SHANG Shiqiang, MAO Jianhua, FU Junfen, SHU Qiang, JIANG Kewen. Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 170-177.
[3] CAO Shengli,FENG Peihua,SHI Pengpeng. Study on the epidemic development of COVID-19 in Hubei province by a modified SEIR model[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 178-184.
[4] CHEN Jun,LIU Danping,LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 215-219.
[5] CHEN Zhimin,FU Junfen,SHU Qiang,WANG Wei,CHEN Yinghu,HUA Chunzhen,LI Fubang,LIN Ru,TANG Lanfang,WANG Tianlin,WANG Yingshuo,XU Weize,YANG Zihao,YE Sheng,YUAN Tianming,ZHANG Chenmei,ZHANG Yuanyuan. Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition)[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 139-146.
[6] XU Kaijin,CAI Hongliu,SHEN Yihong,NI Qin,CHEN Yu,HU Shaohua,LI Jianping,WANG Huafen,YU Liang,HUANG He,QIU Yunqing,WEI Guoqing,FANG Qiang,ZHOU Jianying,SHENG Jifang,LIANG Tingbo,LI Lanjuan. Management of COVID-19: the Zhejiang experience[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 147-157.
[7] JIANG Saiping,LI Lu,RU Renping,ZHANG Chunhong,RAO Yuefeng,LIN Bin,WANG Rongrong,CHEN Na,WANG Xiaojuan,CAI Hongliu,SHENG Jifang,ZHOU Jianying,LU Xiaoyang,QIU Yunqing. Pharmaceutical care for severe and critically ill patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 158-169.
[8] LI Xin,DAI Tian,WANG Hong,SHI Junnian,YUAN Wei,LI Jing,CHEN Lijun,ZHANG Tianming,ZHANG Shanshan,KONG Yan,YUE Ning,SHI Hui,HE Yuping,HU Huifang,LIU Furong,YANG Caixia. Clinical analysis of suspected COVID-19 patients with anxiety and depression[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 203-208.
[9] HONG Dongsheng,NI Jian,SHAN Wenya,LI Lu,HU Xi,YANG Hongyu,ZHAO Qingwei,ZHANG Xingguo. Establishment of a rapid identification of adverse drug reaction program in R language implementation based on monitoring data[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 253-259.
[10] ZHONG Qi,LI Zhi,SHEN Xiaoyong,XU Kaijin,SHEN Yihong,FANG Qiang,CHEN Feng,LIANG Tingbo. CT imaging features of patients with different clinical types of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 198-202.
[11] KANG Xianhui,ZHANG Rong,HE Huiliang,YAO Yongxing,ZHENG Yueying,WEN Xiaohong,ZHU Shengmei. Anesthesia management in cesarean section for patient with COVID-19: a case report[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 249-252.
[12] CHEN Xu,LI Yang,WANG Jinxi,CAI Hongliu,CAO Hongcui,SHENG Jifang. Pregnant women complicated with COVID-19: a clinical analysis of 3 cases[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 240-244.
[13] SHEN Lihua,HUANG Fei,CHEN Xiang,XIONG Zuan,YANG Xiaoyu,LI Hui,CHENG Feng,GUO Jian,GONG Guofu. Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 185-190.
[14] ZHAGN Sheng,LI Danping,CHEN Huazhong,ZHENG Dan,ZHOU Yiping,CHEN Baoguo,SHI Weiwu,LIN Ronghai. Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 220-226.
[15] LI Youjiang,HU Yingying,ZHANG Xiaodong,YU Yuanyuan,LI Bin,WU Jianguo,WU Yingping,XIA Xiaoping,XU Jian. Follow-up testing of viral nucleic acid in discharged patients with moderate type of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 270-274.